AnuMed International, LLC
Has AnuMed International, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated August 20, 2024 concerning products containing semaglutide.
Letter facts
- Letter date
- August 20, 2024 (2024-08-20)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Manufacturer / API
- Products named
- Semaglutide Homeopathic FormulaMagnesium 50 mg Body CreamAnuMed™ 25mg Per Pump PROGESTERONE CREAMAnuMed™ 75mg Per Pump PROGESTERONE CREAMAnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMPAnuMed™ BIO-IDENTICAL BIO-EST 5mg Per PumpAnuMed™ 2.5 All Natural ESTRIOL CREAMAnuMed™ 5.0 All Natural ESTRIOL CREAMAnuMed™ Bio-Identical DHEA 20 CREAMAnuMed™ Bio-Identical DHEA 50 CREAM50,000 IU Vitamin D3+K2 CREAMTravel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health SupportVitamin C Booster - 2000mgImmune Booster 90 CapsulesVegan Vitamin D3 K2 60ct CapsulesB-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)2oz Vitamin C Booster Drops2oz Anumed Zinc DropsTurmeric Curcumin Drops 775mg with Black Pepper Extract
- Violation categories
- Unapproved new drugMisbrandingCGMP / insanitary conditions
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
Factual Violation Summary
FDA cited unapproved new drug claims for numerous products, misbranding through misleading FDA approval or registration statements, and CGMP noncompliance rendering the drugs adulterated; no approved applications were in effect.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- unapproved new drugs
- misbranded drugs
- adulterated drugs (CGMP violations)
More letters about Retatrutide
Recent FDA warning letters concerning Retatrutide:
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
- Peptide Partners LLCAugust 24, 2026
- Peak Performance PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.